Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biogena Group (BIO) Fair Value & Analysis

Consumer Defensive · AT · Market cap €12.2M

BG Biogena Group BIO · VI
Price€4.54
Fair Value€0.8400
Upside-81.5%
Quality89/100
Evidence: Medium Range €0.6300 – €1.04

Fair value as of: Jun 24, 2026

From 13 valuation models · updated 5 days ago

Share price +19.6% over the past month.

Price vs Fair Value (12 months)

€5.68 €3.05 Fair Value €0.8400 Jun 2025 Jun 2026

12‑month range €3.05 – €5.68 · fair‑value band €0.6300 – €1.04 · the €4.54 price screens above the €0.8400 fair value. As of Jun 24, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Biogena Group (BIO) currently trades at €4.54, while our model-based Fair Value estimate is €0.8400 — implying the stock looks roughly 81.5% overvalued today. We read business quality at 89/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

The stock trades on a trailing P/E of 43.7. Fundamentals as of Jun 24, 2026

Key figures & financial health

P/E ratio 43.7
EPS (TTM) €0.0700
Net cash €12.3K FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.

About the company

Biogena Group Invest AG engages in the provision of dietary supplements. The company is based in Salzburg, Austria.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Biogena Group reported revenue of €368K in FY2025 versus €329K in FY2021, a compound +2.8%/yr. Reported net income was €330K in FY2025, compounding +29.7%/yr from FY2021.

Revenue +2.8%/yr
FY21 €329K
FY22 €331K
FY23 €251K
FY24 €166K
FY25 €368K
Net income +29.7%/yr
FY21 €117K
FY22 €735K
FY23 €298K
FY24 €172K
FY25 €330K

Open the full interactive analysis →

Similar stocks

6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).

Stock Price Fair Value vs Fair Value
Nestlé S.A NSRGF $97.58 $65.41 -33%
Foshan Haitian Flavouring and Food Company 603288 ¥35.10 ¥25.34 -28%
Nestlé India Limited NESTLEIND ₹1,386 ₹278.10 -80%
Grupo Bimbo, S.A. BIMBOA 57.10 MXN 45.03 MXN -21%
Uni-President Enterprises Corp 1216 75.60 TWD 55.53 TWD -27%
Britannia Industries Limited BRITANNIA ₹5,218 ₹3,567 -32%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Biogena Group (BIO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.8400 versus a price of €4.54 — about −81% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BIO?
Our 21-model fair value for Biogena Group is €0.8400 (as of Jun 24, 2026), built from audited fundamentals. The current price is €4.54.
What is the quality score of BIO?
Biogena Group has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of BIO?
The net profit margin of Biogena Group is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.